Research ArticleOriginal Research

Use of a Viral Filter to Reduce Exposure to Exhaled Aerosol Does Not Affect Methacholine Dose Delivery During Bronchoprovocation Testing

Yosuf W Subat, Todd J Meyer, Keith D Torgerud, Kaiser G Lim, Paul D Scanlon and Alexander S Niven
Respiratory Care August 2022, 67 (8) 899-905; DOI: https://doi.org/10.4187/respcare.09703

References

  1. 1.↵
    1. Subat YW,
    2. Hainy ME,
    3. Torgerud KD,
    4. Sajgalik P,
    5. Guntupalli SK,
    6. Johnson BD,
    7. et al
    . Aerosol generation and mitigation during methacholine bronchoprovocation testing: infection control implications in the era of COVID-19. Respir Care 2021;66(12):1858-1865.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Coates AL,
    2. Wanger J,
    3. Cockcroft DW,
    4. Culver BH,
    5. Diamant Z,
    6. Gauvreau G,
    7. et al
    ; the Bronchoprovocation Testing Task Force. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J 2017;49(5):1601526.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Tran K,
    2. Cimon K,
    3. Severn M,
    4. Pessoa-Silva CL,
    5. Conly J
    . Aerosol-generating procedures and risk of transmission of acute respiratory infections to health care workers: a systematic review. PLoS One 2012;7(4):e35797-e35797.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Buonanno G,
    2. Stabile L,
    3. Morawska L
    . Estimation of airborne viral emission: quanta emission rate of SARS-CoV-2 for infection risk assessment. Environ Int 2020;141:105794-105794.
    OpenUrlCrossRefPubMed
  5. 5.
    1. Chia PY,
    2. Coleman KK,
    3. Tan YK,
    4. Ong SWX,
    5. Gum M,
    6. Lau SK,
    7. et al
    ; Singapore 2019 Novel Coronavirus Outbreak Research Team. Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. Nat Commun 2020;11(1):2800.
    OpenUrlCrossRefPubMed
  6. 6.
    1. Fears AC,
    2. Klimstra WB,
    3. Duprex P,
    4. Hartman A,
    5. Weaver SC,
    6. Plante KS,
    7. et al
    . Persistence of severe acute respiratory syndrome coronavirus 2 in aerosol suspensions. Emerg Infect Dis 2020;26(9):2168-2171.
    OpenUrl
  7. 7.
    1. Lednicky JA,
    2. Lauzard M,
    3. Fan ZH,
    4. Jutla A,
    5. Tilly TB,
    6. Gangwar M,
    7. et al
    . Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients. Int J Infect Dis 2020;100:476-482.
    OpenUrlCrossRefPubMed
  8. 8.
    1. Liu Y,
    2. Ning Z,
    3. Chen Y,
    4. Guo M,
    5. Liu Y,
    6. Gali NK,
    7. et al
    . Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature 2020;582(7813):557-560.
    OpenUrlPubMed
  9. 9.
    1. Meselson M
    . Droplets and aerosols in the transmission of SARS-CoV-2. N Engl J Med 2020;382(21):2063-2063.
    OpenUrlCrossRefPubMed
  10. 10.
    1. Ong SWX,
    2. Tan YK,
    3. Chia PY,
    4. Lee TH,
    5. Ng OT,
    6. Wong MSY,
    7. et al
    . Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. Jama 2020;323(16):1610-1612.
    OpenUrlCrossRefPubMed
  11. 11.
    1. Santarpia JL,
    2. Rivera DN,
    3. Herrera VL,
    4. Morwitzer MJ,
    5. Creager HM,
    6. Santarpia GW,
    7. et al
    . Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care. Sci Rep 2020;10(1):12732.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Sommerstein R,
    2. Fux CA,
    3. Vuichard-Gysin D,
    4. Abbas M,
    5. Marschall J,
    6. Balmelli C,
    7. et al
    ; Swissnoso. Risk of SARS-CoV-2 transmission by aerosols, the rational use of masks, and protection of health care workers from COVID-19. Antimicrob Resist Infect Control 2020;9(1):100.
    OpenUrl
  13. 13.
    1. Somsen GA,
    2. van Rijn C,
    3. Kooij S,
    4. Bem RA,
    5. Bonn D
    . Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. Lancet Respir Med 2020;8(7):658-659.
    OpenUrl
  14. 14.
    1. Tang S,
    2. Mao Y,
    3. Jones RM,
    4. Tan Q,
    5. Ji JS,
    6. Li N,
    7. et al
    . Aerosol transmission of SARS-CoV-2? Evidence, prevention, and control. Environ Int 2020;144:106039-106039.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. van Doremalen N,
    2. Bushmaker T,
    3. Morris DH,
    4. Holbrook MG,
    5. Gamble A,
    6. Williamson BN,
    7. et al
    . Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382(16):1564-1567.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. US Pharmacopeia General Chapter 797
    . Pharmaceutical Compounding–Sterile Preparations. https://www.usp.org/compounding/general-chapter-797. Accessed September 23, 2021
  17. 17.↵
    1. Subat Y,
    2. Sajgalik P,
    3. Hainy M,
    4. Torgerud K,
    5. Guntupalli SK,
    6. Helgeson S,
    7. et al
    . Aerosol generation during methacholine challenge testing: clinical implications during the COVID-19 pandemic. American Thoracic Society 2021:A4473-A4473.
  18. 18.↵
    1. Dennis JH,
    2. Hendrick DJ
    . Design characteristics for drug nebulizers. J Med Eng Technol 1992;16(2):63-68.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    Methapharm. Nebulizer characterization for the methacholine challenge test. Available at: https://provocholine.com/wp-content/uploads/2021/04/Neb-characterization-technical-bulletin.pdf. Accessed September 23, 2021.
  20. 20.↵
    1. Coates A,
    2. Culver B,
    3. Cockcroft D,
    4. Hallstrand T,
    5. Haynes J,
    6. Kaminsky D,
    7. et al
    . Characterizing nebulizer performance for methacholine challenge tests. Am J Respir Crit Care Med 2018;198(8):988-990.
    OpenUrl
  21. 21.↵
    1. Coates AL,
    2. Leung K,
    3. Dell SD
    . Developing alternative delivery systems for methacholine challenge tests. J Aerosol Med Pulm Drug Deliv 2014;27(1):66-70.
    OpenUrl
  22. 22.↵
    Trudell Medical Corporation. Methacholine guideline recommendations and the AeroEclipse II Breath Actuated Nebulizer. Available at: http://www.amc-ag.ch/wordpress/wp-content/uploads/2018/12/MCT-and-BAN-Dose-Calculation.pdf. Accessed September 23, 2021.
  23. 23.↵
    1. Helgeson SA,
    2. Lee AS,
    3. Patel NM,
    4. Taylor BJ,
    5. Lim KG,
    6. Niven AS
    . Cardiopulmonary exercise and the risk of aerosol generation while wearing a surgical mask. Chest 2021;159(4):1567-1569.
    OpenUrl
  24. 24.
    1. Helgeson SA,
    2. Lim KG,
    3. Lee AS,
    4. Niven AS,
    5. Patel NM
    . Aerosol generation during spirometry. Ann Am Thorac Soc 2020;17(12):1637-1639.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Subat YW,
    2. Guntupalli SK,
    3. Sajgalik P,
    4. Hainy ME,
    5. Torgerud KD,
    6. Helgeson SA,
    7. et al
    . Aerosol generation during peak flow testing: clinical implications for COVID-19. Respir Care 2021.
  26. 26.↵
    1. Li J,
    2. Jing G,
    3. Fink JB,
    4. Porszasz J,
    5. Moran EM,
    6. Kiourkas RD,
    7. et al
    . Airborne particulate concentrations during and after pulmonary function testing. Chest 2021;159(4):1570-1574.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Biddiscombe MF,
    2. Meah SN,
    3. Underwood SR,
    4. Usmani OS
    . Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition. J Aerosol Med Pulm Drug Deliv 2011;24(3):165-173.
    OpenUrlPubMed
  28. 28.↵
    1. Sanchez-Crespo A
    . Lung scintigraphy in the assessment of aerosol deposition and clearance. Semin Nucl Med 2019;49(1):47-57.
    OpenUrl
  29. 29.↵
    1. Cockcroft DW,
    2. Hurst TS,
    3. Gore BP
    . Importance of evaporative water losses during standardized nebulized inhalation provocation tests. Chest 1989;96(3):505-508.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Coates AL,
    2. MacNeish CF,
    3. Allen PD,
    4. Ho SL,
    5. Lands LC
    . Do sinusoidal models of respiration accurately reflect the respiratory events of patients breathing on nebulizers? J Aerosol Med 1999;12(4):265-273.
    OpenUrlPubMed
  31. 31.↵
    1. Laube BL,
    2. Adams GK 3rd.,
    3. Norman PS,
    4. Rosenthal RR
    . The effect of inspiratory flow rate regulation on nebulizer output and on human airway response to methacholine aerosol. J Allergy Clin Immunol 1985;76(5):708-713.
    OpenUrlPubMed
  32. 32.↵
    1. Brain JD,
    2. Valberg PA
    . Deposition of aerosol in the respiratory tract. Am Rev Respir Dis 1979;120(6):1325-1373.
    OpenUrlPubMedWeb of Science
  33. 33.↵
    1. Christiani DC,
    2. Kern DG
    . Asthma risk and occupation as a respiratory therapist. Am Rev Respir Dis 1993;148(3):671-674.
    OpenUrlPubMedWeb of Science
  34. 34.
    1. Dimich-Ward H,
    2. Wymer ML,
    3. Chan-Yeung M
    . Respiratory health survey of respiratory therapists. Chest 2004;126(4):1048-1053.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Kern DG,
    2. Frumkin H
    . Asthma in respiratory therapists. Ann Intern Med 1989;110(10):767-773.
    OpenUrlPubMed
  36. 36.↵
    1. Cockcroft DW
    . Methacholine challenge. PD20 versus PC20. Ann Am Thorac Soc 2015;12(3):291-292.
    OpenUrlCrossRefPubMed
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords